retatrutide phase 2 nejm 2023 percent weight loss 48 weeks study sees significant in obesity drug study Retatrutide, an Amazing Future for

Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose

According to Duah, Patients should be aware of side effects, how to manage the side effects, [and] when to consider stopping the medication if they have side effects

Autophagy is a highly conserved regulatory process responsible for helping cells recycle damaged organelles, facilitating the maintenance of homeostasis 29

The general principle applied to weight-loss medications is that the medication itself may not preclude donation, but the underlying health conditions, treatment response, and overall medical status require comprehensive evaluation